

# SWISS BIOTECH SUCCESS STORY

## BACHEM



Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.

With 50 years of expertise, Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.

Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. At the end of 2020, more than 1000 people were working in Switzerland at Bachem AG sites in Bubendorf and Vionnaz, which is an increase of more than 50% during the last five years.

The company is listed on the SIX Swiss Exchange. For further information, see [www.bachem.com](http://www.bachem.com).



### THE FOUNDER



**Dr. h.c. Peter Grogg**  
Founder and Honorary  
Chairman



### KNOWLEDGE

- Founded in 1971, as Bachem Feinchemikalien AG in Liestal near Basel with the focus on amino acid and peptide synthesis.
- Public company since 1998 (Swiss stock exchange).
- 4 cGMP facilities in Switzerland and the U.S.
- Capacity to produce peptide or oligonucleotide APIs from gram scale up to annual quantities of hundreds of kilograms and small molecules APIs up to hundreds of tons.




### BUSINESS DEVELOPMENT

- Supporting pharma and biotech companies in ~ 150 NCE development projects in different clinical phases.
- Offering more than 5500 different biologically active peptides, amino acid derivatives and oligonucleotides.
- Expanded the portfolio by establishing itself as a full-service provider for the development and production of oligonucleotides.
- The Green Chemistry Award bestowed on Bachem by the US Environmental Protection Agency (EPA) for a jointly developed project underscores Bachem's dedication to improving environmental aspects of production processes.
- In 2018, Bachem established a sales office in Tokyo, Japan. This new local presence in Asia will strengthen customer support and drive further business growth in the Asian market.
- The research and development building in Bubendorf, Switzerland, marks a recent milestone in the development of the Bachem Group's largest production site. Further expansion plans will be realized in the next years.
- With investment plans for over 400 million CHF in the next five years, the Bachem Group will continue to pursue its ambitious growth strategy.

## SUCCESS CATEGORIES

- ★ Completed achievement with lasting impact
- ★ Product approval and sustainable revenues
- ★ Involvement of one or more Swiss citizens
- ★ Swiss based company / institution
- ★ Creation of jobs in Switzerland
- ★ Enabler for the biotech industry
- ★ Swissness: Think global, made in Switzerland

**SWISS**   
**BIOTECH**™

Organized by

